MYRIAD GENETICS INC 8-K

What Happened
Myriad Genetics, Inc. filed a Form 8‑K on June 4, 2026 reporting that its stockholders approved two compensation plan changes at the company’s 2026 Annual Meeting. Shareholders approved an amendment to the Amended and Restated 2012 Employee Stock Purchase Plan (ESPP) to add 4,000,000 shares. They also approved the company’s new 2026 Employee, Director and Consultant Equity Incentive Plan (the “2026 Plan”), which provides for an initial issuance of shares for equity awards and rolls over remaining availability from the prior 2017 Plan. The filing references the company’s proxy statement filed April 14, 2026 and attaches the two plans as exhibits.

Key Details

• ESPP amendment: increases shares authorized under the Amended and Restated 2012 Employee Stock Purchase Plan by 4,000,000 shares.
• 2026 Equity Plan: initial new issuance of 6,400,000 shares plus 2,063,567 shares rolled over from the 2017 Plan, for a total of 8,463,567 shares available at approval.
• Reserve adjustment: the 2026 Plan reserve may increase by shares from forfeited/expired/cancelled awards under the 2017 Plan up to a maximum of 8,659,575 shares. No future awards will be granted under the 2017 Plan.
• Administrative notes: summaries of plan terms are in the April 14, 2026 proxy; the final plan documents are attached as Exhibits 10.1 and 10.2 to the 8‑K. The report was signed by CFO Benjamin R. Wheeler.

Why It Matters
These approvals give Myriad the formal ability to issue additional shares for employee stock purchases and equity compensation. For investors, the immediate facts to note are the exact share increases (4,000,000 for the ESPP; 8,463,567 initial reserve for the 2026 Plan) because new awards and purchases can increase the company’s share count and affect dilution over time. The rollover and forfeiture provisions mean available shares for grants can change, so watch future equity grant disclosures and updates to the company’s outstanding share count. Keywords: equity plan, ESPP, shareholder vote, dilution, employee compensation.